Q5150 Injection, aflibercept-mrbb, 1 milligrams
Also known as: aflibercept biosimilar, Fabhalta, VEGF inhibitor, anti-VEGF
Injection of aflibercept-mrbb (Fabhalta), a biosimilar to aflibercept, administered at 1 milligram per dose.
In Plain Language
eye injection; macular degeneration treatment; retinal medication
Clinical Context
Used for wet age-related macular degeneration treatment with intravitreal administration. Provides vascular endothelial growth factor inhibition for neovascular disease management.
RVU Information
CPT Q5150 does not have a physician work RVU assigned by CMS. Reimbursement for this code is determined by payer-specific fee schedules.
Billing & Documentation
Q-codes are temporary HCPCS codes used when no permanent code exists. Coverage and reimbursement vary by payer and region. Document the clinical indication and medical necessity. These codes may be replaced by permanent codes in future HCPCS updates.
Specialties
Frequently Asked Questions
What is CPT code Q5150?
CPT Q5150 (Injection, aflibercept-mrbb, 1 milligrams) is a Q Codes code. Injection of aflibercept-mrbb (Fabhalta), a biosimilar to aflibercept, administered at 1 milligram per dose.
Is Q5150 covered by insurance?
Q5150 is a temporary HCPCS code. Coverage varies by payer and may change when permanent codes are assigned. Used for wet age-related macular degeneration treatment with intravitreal administration. Provides vascular endothelial growth factor inhibition for neovascular disease management.
When is CPT Q5150 used?
Used for wet age-related macular degeneration treatment with intravitreal administration. Provides vascular endothelial growth factor inhibition for neovascular disease management.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against national data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.